Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014–2015 season

Vaccine

Volumn 35, Issue 20, 2017, Pages 2685-2693

  McLean, Huong Q ^a   Caspard, Herve ^b   Griffin, Marie R ^c   Poehling, Katherine A ^d   Gaglani, Manjusha ^e   Belongia, Edward A ^a   Talbot, H Keipp ^c   Peters, Timothy R ^d   Murthy, Kempapura ^e   Ambrose, Christopher S ^b  

^a MARSHFIELD CLINIC   (United States)

^b MEDIMMUNE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Influenza; Influenza vaccine; Pediatrics; Vaccine effectiveness

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; ANTIGENIC VARIATION; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FEVER; HUMAN; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NOSE SMEAR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ISOLATION; VIRUS STRAIN; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; ISOLATION AND PURIFICATION; PHARYNX; PRESCHOOL CHILD; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PHARYNX; TREATMENT OUTCOME; UNITED STATES; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 85017373284     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.03.085     Document Type: Article

References (27)

1. [1] Fiore, A.E., Shay, D.K., Broder, K., Iskander, J.K., Uyeki, T.M., Mootrey, G., et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57:RR-7 (2008), 1–60.
2. [2] Grohskopf, L.A., Olsen, S.J., Sokolow, L.Z., Bresee, J.S., Cox, N.J., Broder, K.R., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 63:32 (2014), 691–697.
3. [3] Ashkenazi, S., Vertruyen, A., Aristegui, J., Esposito, S., McKeith, D.D., Klemola, T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25:10 (2006), 870–879, 10.1097/01.inf.0000237829.66310.85.
4. [4] Belshe, R.B., Edwards, K.M., Vesikari, T., Black, S.V., Walker, R.E., Hultquist, M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:7 (2007), 685–696, 10.1056/NEJMoa065368.
5. [5] Ambrose, C.S., Wu, X., Knuf, M., Wutzler, P., The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 30:5 (2012), 886–892, 10.1016/j.vaccine.2011.11.104.
6. [6] Chung, J.R., Flannery, B., Thompson, M.G., Gaglani, M., Jackson, M.L., Monto, A.S., et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 137:2 (2016), 1–10, 10.1542/peds.2015-3279.
7. [7] Caspard, H., Gaglani, M., Clipper, L., Belongia, E.A., McLean, H.Q., Griffin, M.R., et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the United States. Vaccine 34:1 (2016), 77–82, 10.1016/j.vaccine.2015.11.010.
8. [8] Gaglani, M., Pruszynski, J., Murthy, K., Clipper, L., Robertson, A., Reis, M., et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013–2014 in the United States. J Infect Dis 213:10 (2016), 1546–1556, 10.1093/infdis/jiv577.
9. [9] Flannery, B., Zimmerman, R.K., Gubareva, L.V., Garten, R.J., Chung, J.R., Nowalk, M.P., et al. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014–2015. J Infect Dis 214:7 (2016), 1010–1019, 10.1093/infdis/jiw181.
10. [10] McLean, H.Q., Thompson, M.G., Sundaram, M.E., Meece, J.K., McClure, D.L., Friedrich, T.C., et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 59:10 (2014), 1375–1385, 10.1093/cid/ciu680.
11. [11] Ohmit, S.E., Petrie, J.G., Malosh, R.E., Fry, A.M., Thompson, M.G., Monto, A.S., Influenza vaccine effectiveness in households with children during the 2012–2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis 211:10 (2015), 1519–1528, 10.1093/infdis/jiu650.
12. [12] Ohmit, S.E., Thompson, M.G., Petrie, J.G., Thaker, S.N., Jackson, M.L., Belongia, E.A., et al. Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 58:3 (2014), 319–327, 10.1093/cid/cit736.
13. [13] Ohmit, S.E., Petrie, J.G., Malosh, R.E., Cowling, B.J., Thompson, M.G., Shay, D.K., et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 56:10 (2013), 1363–1369, 10.1093/cid/cit060.
14. [14] Lindstrom, S., Garten, R., Balish, A., Shu, B., Emery, S., Berman, L., et al. Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Emerg Infect Dis 18:5 (2012), 834–837, 10.3201/eid1805.111922.
15. [15] Skowronski, D.M., Janjua, N.Z., De Serres, G., Winter, A.L., Dickinson, J.A., Gardy, J.L., et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010–2011 season. Clin Infect Dis 55:3 (2012), 332–342, 10.1093/cid/cis431.
16. [16] Foppa, I.M., Haber, M., Ferdinands, J.M., Shay, D.K., The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 31:30 (2013), 3104–3109, 10.1016/j.vaccine.2013.04.026.
17. [17] Jackson, M.L., Nelson, J.C., The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31:17 (2013), 2165–2168, 10.1016/j.vaccine.2013.02.053.
18. [18] McLean, H.Q., Thompson, M.G., Sundaram, M.E., Kieke, B.A., Gaglani, M., Murthy, K., et al. Influenza vaccine effectiveness in the United States during 2012–2013: variable protection by age and virus type. J Infect Dis 211:10 (2015), 1529–1540, 10.1093/infdis/jiu647.
19. [19] Pebody, R., Warburton, F., Andrews, N., Ellis, J., von Wissmann, B., Robertson, C., et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill, 20(36), 2015, 10.2807/1560-7917.ES.2015.20.36.30013.
20. [20] Flannery B. End-of-season influenza vaccine effectiveness estimates for the 2014–15 season: US Influenza Vaccine Effectiveness (Flu VE) Network. Meeting of the Advisory Committee on Immunization Practices; June 24–25, 2015; Atlanta, GA.
21. [21] Skowronski, D.M., Chambers, C., Sabaiduc, S., De Serres, G., Winter, A.L., Dickinson, J.A., et al. A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 season. Clin Infect Dis 63:1 (2016), 21–32, 10.1093/cid/ciw176.
22. [22] Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horvath JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill 2016;21(7). http://dx.doi.org/10.2807/1560-7917.ES.2016.21.7.30139.
23. [23] Rajaram S, Bright H, Ambrose CS. Protection of live attenuated influenza vaccine against antigenically mismatched influenza A(H3N2) strains (Abstract #P-593). Options IX for the Control of Influenza; August 24–28, 2016; Chicago, IL.
24. [24] Grohskopf, L.A., Sokolow, L.Z., Broder, K.R., Olsen, S.J., Karron, R.A., Jernigan, D.B., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2016–17 influenza season. MMWR Recomm Rep 65:5 (2016), 1–54, 10.15585/mmwr.rr6505a1.
25. [25] Grohskopf, L.A., Sokolow, L.Z., Olsen, S.J., Bresee, J.S., Broder, K.R., Karron, R.A., Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 influenza season. MMWR Morb Mortal Wkly Rep 64:30 (2015), 818–825.
26. [26] Zimmerman RK, Nowalk MP, Chung JR, Jackson ML, Jackson LA, Petrie JG, et al. 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis 2016 Oct 4. pii: ciw635 [Epub ahead of print].
27. [27] Mosterin Hopping, A., McElhaney, J., Fonville, J.M., Powers, D.C., Beyer, W.E., Smith, D.J., The confounded effects of age and exposure history in response to influenza vaccination. Vaccine 34:4 (2016), 540–546, 10.1016/j.vaccine.2015.11.058.